We posit that targeting a TF isoform that is dispensable to hemostasis, yet possibly more deleterious than flTF as a cancer driver due to its solubility and autocrine effects on cancer cells, may comprise a new and promising avenue in cancer patient care. The gene discussed is TF; the disease is cancer.